Exagen Inc. Reports Fourth Quarter and Full Year 2022 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Exagen Inc. (XGN) Misses Q4 EPS by 6c, Revenue Beats, Offers Guidance
March 20, 2023 4:08 PM EDTExagen Inc. (NASDAQ: XGN) reported Q4 EPS of ($0.83), $0.06 worse than the analyst estimate of ($0.77). Revenue for the quarter came in at $12.8 million versus the consensus estimate of $8.66 million.
GUIDANCE:
Exagen Inc. sees Q1 2023 revenue of $9.2-9.7 million, versus the consensus... More
